You can now review and comment on this draft guideline.
The consultation closes on 12 October 2023, 5pm
How to comment
1. Register your organisation or comment as an individual
If you’re commenting for an organisation, your organisation needs to be registered as a stakeholder.
Not eligible? Contact the stakeholder organisation that most closely represents your interests and pass your comments to them.
We can accept comments from individuals. These will be considered, but you won’t get a formal response and they won’t be posted on the NICE website. Wherever possible we encourage you to submit your comments through a registered stakeholder organisation.
2. Read the consultation documents
Documents to comment on:
- Draft guideline
- Evidence review A1 - Symptoms & signs BM
- Evidence review A2 - Risk factors BM.pdf
- Evidence review A3 - Symptoms & signs MDEvidence review D3 - Antibiotics unknown adults BM
- Evidence review A4 - Risk factors MD.pdf
- Evidence review B1 - Blood & urine investigations BM
- Evidence review B2 - Blood & urine investigations MD
- Evidence review B3 - CSF parameters BM
- Evidence review B4 - Brain herniation
- Evidence review B5 - Neuroimaging prior to lumbar puncture
- Evidence review C1 - Antibiotic timing BM
- Evidence review C2 - Antibiotic timing MD
- Evidence review D1 - Antibiotics unknown younger infants BM
- Evidence review D2 - Antibiotics unknown older infants BM
- Evidence review D3 - Antibiotics unknown adults BM
- Evidence review E1 - Antibiotics strep pneumoniae BM
- Evidence review E2 - Antibiotics haemophilis influenzae BM
- Evidence review E3 - Antibiotics group B strep BM
- Evidence review E4 - Antibiotics gram negative bacilli BM
- Evidence review E5 - Antibiotics listeria BM
- Evidence review E6 - Antibiotics neisseria BM
- Evidence review F1 - Antibiotics for MD
- Evidence review G1 - Fluid restriction
- Evidence review G2 - Osmotic agents BM
- Evidence review G3 - ICP monitoring BM
- Evidence review G4 - Corticosteroids BM
- Evidence review H - Corticosteroids MD
- Evidence review I1 - Long term complications BM
- Evidence review I2 - Long term complications MD
- Evidence review J1 - Recurrent BM
- Evidence review J2 - Recurrent MD
- Evidence review K1 - Info for suspected BM or MD
- Evidence review K2 - Support for suspected BM or MD
- Evidence review K3 - Info confirmed BM or MD
- Evidence review K4 - Support confirmed BM or MD
Other information about the consultation
Developing NICE guidelines: how to get involved
- Final scope – for information
3. Add your comments
- You must use this Comments form.
- You must declare any links with, or funding from, the tobacco industry
If you share similar views with another organisation, send a joint response.
Make sure you consider:
- The areas that will have the biggest impact on practice and be challenging to implement
- How to help users overcome challenges
Developing NICE guidelines: how to get involved suggests some other areas to comment on.
4. Email the form to us
Email: meningitis&meningococcal@nice.org.uk
Deadline: 12 October 2023, 5pm
This page was last updated: